This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Cumberland Pharmaceuticals Inc.
Drug Names(s): intravenous ifetroban
BioMedTracker has separate profiles for the injectable and oral formulations of ifetreoban. Please also see Boxaban.
Hepatorenis the injectable version of the ifetreoban. Ifetroban is a pharmacological antagonist of the thromboxane A2 / prostaglandin endoperoxide receptor (TPR). Ifetroban exhibits high-affinity for TPRs on platelets, vascular smooth muscle and certain other cell types and lacks agonistic activity. Ifetroban also displays anti-platelet and antivasospastic activities and is effective in certain preclinical models of vasospasm, thrombosis, reperfusion injury and endothelial dysfunction, including models that are insensitive to aspirin.
Deal Structure: Ifetroban was originally developed by Bristol-Myers Squibb (BMS). BMS conducted extensive preclinical and clinical studies, including seven Phase II trials for its own target indications, and eventually donated the entire program to Vanderbilt University.
In April 2011, Cumberland acquired the ifetroban program from Vanderbilt, assuming responsibility for development and commercialization of the product. Cumberland's acquisition of the ifetroban program includes rights to an extensive clinical database and non-clinical data package as well as manufacturing processes, know-how and intellectual property related to the product.
Additional information available to subscribers only: